Tech Company Financing Transactions

CoMentis Funding Round

On 9/28/2006, CoMentis secured $50 million in Series B funding from Clarus, Sanderling Ventures and CLS.

Transaction Overview

Company Name
Announced On
9/28/2006
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors

Clarus (Lead Investor) (Dennis Henner)

Sanderling Ventures (Lead Investor)

CLS

Index Ventures

Proceeds Purpose
The funds will be used primarily to advance development of the company's lead programs targeting Alzheimer's disease, age-related macular degeneration (AMD) and cognition enhancement.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Oyster Point Blvd. 226
San Francisco, CA 94080
USA
Email Address
Not Recorded
Overview
CoMentis is a biotech company engaged in the research and development of small molecule drugs to treat neurovascular diseases.
Profile
CoMentis LinkedIn Company Profile
Social Media
CoMentis Company Twitter Account
Company News
CoMentis News
Facebook
CoMentis on Facebook
YouTube
CoMentis on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Terence Kelly
  Terence Kelly LinkedIn Profile  Terence Kelly Twitter Account  Terence Kelly News  Terence Kelly on Facebook
VP - General Counsel
Daniel Hunt
  Daniel Hunt LinkedIn Profile  Daniel Hunt Twitter Account  Daniel Hunt News  Daniel Hunt on Facebook
VP - R & D
John Ng
  John Ng LinkedIn Profile  John Ng Twitter Account  John Ng News  John Ng on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/28/2006: Demand Media venture capital transaction
Next: 9/29/2006: NovaCardia venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary